Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...
Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
The New York State Senate has unanimously passed Senate Bill S. 2000, a significant step toward improving the early detection ...
Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall ...
Study Finds on MSN9d
‘Western Diet’ May Create Cancer-Friendly Conditions in the LungsDiscover how diet affects lung cancer risk. Learn about the link between a high-fat, high-sugar diet and lung cancer ...
SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...
"Lung cancer ranks third in terms of new cases but second in terms of mortality in Vietnam. Of the over 24,000 new cases ...
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback